{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epoetin+Alfa+plus+Iron", "query": { "intervention": "Epoetin Alfa plus Iron" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epoetin+Alfa+plus+Iron&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T05:55:02.942Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02504294", "title": "A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Kidney Disease (CKD)" ], "interventions": [ { "name": "Epoetin Hospira Arm", "type": "BIOLOGICAL" }, { "name": "Standard of Care Arm", "type": "OTHER" }, { "name": "IV Iron", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 432, "start_date": "2015-07-13", "completion_date": "2016-07-16", "has_results": true, "last_update_posted_date": "2018-06-13", "last_synced_at": "2026-10-01T05:55:02.942Z", "location_count": 42, "location_summary": "Chula Vista, California • Poway, California • Rancho Bernardo, California + 24 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Poway", "state": "California" }, { "city": "Rancho Bernardo", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02504294" }, { "nct_id": "NCT00224081", "title": "DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Anemia, Iron-Deficiency", "Kidney Failure, Chronic", "Hemodialysis" ], "interventions": [ { "name": "Sodium ferric gluconate,", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Watson Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2004-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-12-10", "last_synced_at": "2026-10-01T05:55:02.942Z", "location_count": 29, "location_summary": "Bakersfield, California • Glendale, California • Los Angeles, California + 26 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00224081" }, { "nct_id": "NCT01888003", "title": "The Benefits of a Preoperative Anemia Management Program", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anemia, Iron-Deficiency" ], "interventions": [ { "name": "Iron sucrose", "type": "DRUG" }, { "name": "Epoetin Alfa", "type": "DRUG" }, { "name": "Blood Transfusion", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "19 Years to 80 Years" }, "enrollment_count": 51, "start_date": "2013-04", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2015-05-28", "last_synced_at": "2026-10-01T05:55:02.942Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01888003" }, { "nct_id": "NCT02876835", "title": "Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anaemia" ], "interventions": [ { "name": "Daprodustat", "type": "DRUG" }, { "name": "Darbepoetin alfa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Iron Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 3872, "start_date": "2016-09-27", "completion_date": "2021-04-19", "has_results": true, "last_update_posted_date": "2024-04-02", "last_synced_at": "2026-10-01T05:55:02.942Z", "location_count": 161, "location_summary": "Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 128 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02876835" }, { "nct_id": "NCT00661999", "title": "Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Precancerous Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "darbepoetin alfa", "type": "BIOLOGICAL" }, { "name": "ferrous sulfate", "type": "DIETARY_SUPPLEMENT" }, { "name": "sodium ferric gluconate complex in sucrose", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DIETARY_SUPPLEMENT", "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 502, "start_date": "2006-01", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2011-05-17", "last_synced_at": "2026-10-01T05:55:02.942Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00661999" }, { "nct_id": "NCT05340465", "title": "Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prematurity", "Iron-deficiency", "Iron Deficiency Anemia", "Iron Malabsorption" ], "interventions": [ { "name": "Darbepoetin Alfa", "type": "DRUG" }, { "name": "Low Molecular Weight Iron Dextran", "type": "DRUG" }, { "name": "Ferumoxytol injection", "type": "DRUG" }, { "name": "Oral iron supplements", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "3 Days", "sex": "ALL", "summary": "Up to 3 Days" }, "enrollment_count": 120, "start_date": "2022-11-27", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-10-01T05:55:02.942Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05340465" }, { "nct_id": "NCT03029208", "title": "Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anaemia" ], "interventions": [ { "name": "Daprodustat", "type": "DRUG" }, { "name": "Darbepoetin alfa", "type": "DRUG" }, { "name": "Iron therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 312, "start_date": "2017-05-11", "completion_date": "2020-09-24", "has_results": true, "last_update_posted_date": "2021-10-20", "last_synced_at": "2026-10-01T05:55:02.942Z", "location_count": 36, "location_summary": "Anaheim, California • Cerritos, California • Escondido, California + 31 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "La Palma", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03029208" }, { "nct_id": "NCT02879305", "title": "Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anaemia", "Aspergillosis, Allergic Bronchopulmonary" ], "interventions": [ { "name": "Daprodustat", "type": "DRUG" }, { "name": "rhEPO", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Iron therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 2964, "start_date": "2016-09-28", "completion_date": "2020-11-09", "has_results": true, "last_update_posted_date": "2021-12-03", "last_synced_at": "2026-10-01T05:55:02.942Z", "location_count": 126, "location_summary": "Huntsville, Alabama • Pine Bluff, Arkansas • Anaheim, California + 103 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02879305" }, { "nct_id": "NCT00481624", "title": "Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anemia" ], "interventions": [ { "name": "Epoetin Alfa plus Iron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Louisville", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2007-05", "completion_date": "2009-11", "has_results": false, "last_update_posted_date": "2018-03-05", "last_synced_at": "2026-10-01T05:55:02.942Z", "location_count": 1, "location_summary": "Louisville, Kentucky", "locations": [ { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT00481624" }, { "nct_id": "NCT02564796", "title": "Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cyanotic Congenital Heart Disease", "Anemia", "Cyanosis", "Congenital Heart Disease" ], "interventions": [ { "name": "Epoetin Alfa and Iron", "type": "DRUG" }, { "name": "Iron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "8 Weeks", "sex": "ALL", "summary": "Up to 8 Weeks" }, "enrollment_count": 4, "start_date": "2016-11", "completion_date": "2020-06", "has_results": true, "last_update_posted_date": "2021-12-02", "last_synced_at": "2026-10-01T05:55:02.942Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02564796" } ] }